Benzinga's Top #PreMarket Gainers

shares jumped 97.11 percent to $35.48 in pre-market trading following Wednesday's announcement that Rhopressa Phase 3 trial has achieved primary endpoint.

shares rose 36.05 percent to $2.34 in pre-market trading following announcement of the FDA Fast Track Designation for its CF102 in the treatment of liver cancer.

shares rose 16.40 percent to $33.22 in pre-market trading after Altice SA agreed to buy Cablevision Systems for around $17.7 billion.

shares climbed 11.20 percent to $30.98 in pre-market trading after the company reported better-than-expected earnings for its fiscal first quarter and issued a strong forecast for the current quarter.

gained 5.09 percent to $7.85 in pre-market trading. Inovio Pharmaceuticals publishes successful Phase 2b trial results of its HPV immunotherapy in The Lancet.